<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6214">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044771</url>
  </required_header>
  <id_info>
    <org_study_id>RALPIR</org_study_id>
    <nct_id>NCT01044771</nct_id>
  </id_info>
  <brief_title>Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria</brief_title>
  <acronym>RALPIR</acronym>
  <official_title>A Pilot Study to Evaluate the Effectiveness of a Tenofovir Raltegravir Switch in Resolving Tenofovir Induced Proteinuria in HIV Infected Individuals With Undetectable HIV Viral Loads</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metropolis Medical</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Metropolis Medical</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the proportion of patients with tenofovir induced
      proteinuria that will resolve their proteinuria when the tenofovir containing
      nucleoside/nucleotide backbone is switched to a raltegravir backbone. Common HIV treatment
      regimens contain nucleoside/nucleotide combinations that may have long-term side effects
      including nephrotoxicity. Switching these backbones out for an integrase inhibitor based
      regimen has not been systematically evaluated.

      Hypothesis: Proteinuria developing during treatment with tenofovir improves or resolves when
      tenofovir is switched out with raltegravir. Switching to a nuc- sparing regimen, containing
      raltegravir and a boosted protease inhibitor in patients without preexisting protease
      inhibitor mutations is safe and does not lead to virologic failure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As described in the brief summary, this is a pilot study to evaluate for improvements in
      proteinuria when switched off from Tenofovir
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Patients With Reduced or Resolved Proteinuria</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measurement of Protein in Urine samples at end of study visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients Without HIV Re-bound</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HIV Viral load blood test at week 24</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV Infections</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>change from tenofovir to raltegravir</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single arm study:
Tenofovir containing nucleoside backbone changed over to raltegravir in all patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>change from tenofovir to raltegravir</intervention_name>
    <description>Change of the tenofovir based nucleoside part of the HIV regimen to raltegravir, 400mg BID</description>
    <arm_group_label>change from tenofovir to raltegravir</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV infection

          -  Ability to comply to protocol requirements

          -  On stable HAART for minimum of 12 weeks

          -  Evidence of TDF induced proteinuria

          -  No evidence of prior Protease inhibitor failure

          -  Treatment-na√Øve to integrase inhibitors

          -  VL&lt;200 x 12 weeks (minimum of 2 viral load measurements)

        Exclusion Criteria:

          -  Active Hepatitis B infection

          -  Proteinuria predating tenofovir use

          -  PRAMs on historic GT or PT

          -  Life expectancy less than 6 months

          -  Subjects with any ongoing AIDS defining illness

          -  Any condition which could compromise the safety of study subject

          -  Grade 3 or 4 lab abnormalities (excl. grade 3 bilirubin elevations)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fritz Bredeek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metropolis Medical</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 8, 2015</lastchanged_date>
  <firstreceived_date>January 6, 2010</firstreceived_date>
  <firstreceived_results_date>January 20, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Metropolis Medical</investigator_affiliation>
    <investigator_full_name>Fritz Bredeek, MD, PhD</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Human immunodeficiency virus</keyword>
  <keyword>tenofovir</keyword>
  <keyword>viread</keyword>
  <keyword>truvada</keyword>
  <keyword>proteinuria</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Tenofovir disoproxil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Change From Tenofovir to Raltegravir</title>
          <description>Single arm study:
Tenofovir containing nucleoside backbone changed over to raltegravir in all patients Tenovovir 300mg was replaced with Raltegravir 400mg twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>HIV</population>
      <group_list>
        <group group_id="B1">
          <title>Change From Tenofovir to Raltegravir</title>
          <description>Single arm study:
Tenofovir containing nucleoside backbone changed over to raltegravir in all patients</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients With Reduced or Resolved Proteinuria</title>
        <description>Measurement of Protein in Urine samples at end of study visit</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Change From Tenofovir to Raltegravir</title>
            <description>Single arm study:
Tenofovir containing nucleoside backbone changed over to raltegravir in all patients
change from tenofovir to raltegravir: Change of the tenofovir based nucleoside part of the HIV regimen to raltegravir, 400mg BID</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patients With Reduced or Resolved Proteinuria</title>
            <description>Measurement of Protein in Urine samples at end of study visit</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Without HIV Re-bound</title>
        <description>HIV Viral load blood test at week 24</description>
        <time_frame>24 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Subjects entered with undetectable Viral Load and Proteinuria</population>
        <group_list>
          <group group_id="O1">
            <title>Viral Rebound</title>
            <description>Every participant in the study switched to the investigational strategy</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patients Without HIV Re-bound</title>
            <description>HIV Viral load blood test at week 24</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during the study and 4 weeks after end of study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Change From Tenofovir to Raltegravir</title>
          <description>Single arm study:
Tenofovir containing nucleoside backbone changed over to raltegravir in all patients</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Fritz Bredeek</name_or_title>
      <organization>Metropolis Medical</organization>
      <phone>415 292 5477</phone>
      <email>fritz@doctor.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
